TYRO3

TYRO3 Informations sur la molécule

Nom anglais	TYRO3 protein tyrosine kinase	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1	Alias de la cible	Tyrosine-Protein Kinase RSE，BYK，Tyrosine-Protein Kinase Receptor TYRO3，Tyrosine-Protein Kinase BYK，Etk-2，Rek，DTK，SKY，TIF，Brt，RSE，Tyrosine-protein kinase DTK，Tyrosine-protein kinase SKY，TYRO3，Tyrosine-protein kinase TIF，TYRO3 Protein Tyrosine Kinase
Phase de R&D la plus avancée	Approved

Nom anglais	TYRO3 protein tyrosine kinase
Alias de la cible	Tyrosine-Protein Kinase RSE，BYK，Tyrosine-Protein Kinase Receptor TYRO3，Tyrosine-Protein Kinase BYK，Etk-2，Rek，DTK，SKY，TIF，Brt，RSE，Tyrosine-protein kinase DTK，Tyrosine-protein kinase SKY，TYRO3，Tyrosine-protein kinase TIF，TYRO3 Protein Tyrosine Kinase
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Approved

TYRO3 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
TY3-H5251	Human	HEK293	Human TYRO3 / Dtk Protein, Fc Tag				Ajouter au panier

Quantité totale1

TYRO3Contexte de la molécule

Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.

TYRO3Alias de la molécule

TYRO3,BYK,DTK,RSE,SKY,TIF

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Insulin transdermal (Phosphagenics)	TPM-02	Phase 2 Clinical	Phosphagenics	Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Primary Ovarian Insufficiency	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Cabozantinib S-malate	XL-184; BMS-907351; RO7047650; RO-7047650	Approved	Exelixis Inc	Cometriq, Cabometyx	United States	Thyroid Neoplasms; Carcinoma, Neuroendocrine	Exelixis Inc	2012-11-29	Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin	Details